A new report tentatively indicates that certain preventative screenings may offer diminishing returns for patients who have already exceeded the average human lifespan. However, researchers caution that these findings are observational and urge patients not to prematurely cancel their scheduled invasive procedures.
A retrospective analysis of Medicare data published this week in JAMA Internal Medicine suggests a potential, though not definitively proven, correlation between being 98 years old and not needing a routine screening for slowly progressing diseases. The researchers emphasize that while routine colonoscopies and prostate-specific antigen tests are generally designed to catch cancers that might develop over the next two to three decades, the decision to forego them in centenarians should still be approached with an abundance of caution and made on a strictly case-by-case basis.
While the data indicates a possible lack of long-term utility in screening a 102-year-old for a disease that takes thirty years to become symptomatic, we must avoid drawing hasty conclusions.
The authors of the study note several limitations to their findings, including the statistical anomaly that all subjects in the oldest control group eventually died of natural causes, making longitudinal health outcomes difficult to parse. Until randomized, double-blind trials can definitively prove that extreme old age is a terminal condition, the American College of Physicians recommends that elderly patients continue to discuss the hypothetical benefits of preventive biopsies with their care providers.